1921
Volume 99, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

The Sri Lankan Anti-Filariasis campaign distributed five rounds of mass drug administration (MDA with diethylcarbamazine plus albendazole) to some 10 million people in eight districts between 2002 and 2006. Sri Lanka was recognized by the WHO for having eliminated lymphatic filariasis (LF) as a public health problem in 2016. However, recent studies by our group documented pockets with persistent LF in coastal Sri Lanka, especially in Galle district. The present study was performed to reexamine an area previously identified as a potential hotspot for persistent LF (Balapitiya Public Health Inspector area, population 17,500). A community survey documented high rates for circulating filarial antigenemia (3%, confidence interval [CI]: 1.8–4.9) and microfilaremia (1%, CI: 0.5–2.5%). Circulating filarial antigenemia rates were 2.8-fold higher in males than females. High prevalence was also observed for anti-filarial antibodies in young children (5.7%, CI: 3.7–8.4%) and for filarial DNA in vector mosquitoes (5.2%, CI: 4.2–6.3%). Spatial data showed that persistent LF was dispersed across the entire study area. Other studies showed that persistent LF was not limited to Balapitiya and not solved by additional rounds of MDA. Molecular xenomonitoring studies conducted in 2016 in 22 of 168 Public Health Midwife areas in the coastal Galle evaluation unit (approximate population 600,000) found that 179 of 660 (27%) pools of collected from all areas were positive for DNA by quantitative polymerase chain reaction; the estimated infection rate in mosquitoes was 1.26%, CI: 1.0–1.5%. Interventions other than routine MDA will be required to remove LF hotspots in Balapitiya and in other areas in coastal Sri Lanka.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.18-0169
2018-09-05
2018-10-18
Loading full text...

Full text loading...

/deliver/fulltext/14761645/99/3/tpmd180169.html?itemId=/content/journals/10.4269/ajtmh.18-0169&mimeType=html&fmt=ahah

References

  1. Abdulcader MH, Rajakone P, Rajendran K, Aponso L, , 1966. Age, sex, and house distribution of Wuchereria bancrofti microfilaremia in Ceylon. Am J Trop Med Hyg 15: 519522.
  2. Sasa M, , 1976. Human Filariasis: A Global Survey of Epidemiology and Control. Tokyo, Japan: University of Tokyo Press, 1–819.
  3. Schweinfurth U, , 1983. Filarial diseases in Ceylon: a geographic and historical analysis. Ecol Dis 2: 309319.
  4. Dissanaike AS, , 1991. Filariasis in Ceylon then (1961) and in Sri Lanka now (1990-30 years on). Ann Trop Med Parasitol 85: 123129.
  5. WHO. Neglected Tropical Diseases. PCT Data Bank. Available at: http://www.who.int/neglected_diseases/preventive_chemotherapy/lf/en/. Accessed April 10, 2018.
  6. WHO, 2012. Expert Mission to Sri Lanka for Verification of Elimination of Lymphatic Filariasis. Report. World Health Organization (SEA-CD-245): New Delhi, India, 1–37.
  7. WHO, 2015. Global programme to eliminate lymphatic filariasis: progress report, 2014. Wkly Epidemiol Rec 90: 489504.
  8. Chu BK, 2013. Transmission assessment surveys (TAS) to define endpoints for lymphatic filariasis mass drug administration: a multicenter evaluation. PLoS Negl Trop Dis 7: e2584.
  9. Rao RU, Nagodavithana KC, Samarasekera SD, Wijegunawardana AD, Premakumara WD, Perera SN, Settinayake S, Miller JP, Weil GJ, , 2014. A comprehensive assessment of lymphatic filariasis in Sri Lanka six years after cessation of mass drug administration. PLoS Negl Trop Dis 8: e3281.
  10. WHO, 2016. Maldives and Sri Lanka Eliminate Lymphatic Filariasis. WHO SEAR/PR/1626. Available at: http://www.searo.who.int/mediacentre/releases/2016/1626/en/. Accessed on April 10, 2018.
  11. WHO, 2016. A Nation Rejoices. Elimination of Filariasis in Sri Lanka. SEARO WHO. Available at: https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=4&cad=rja&uact=8&ved=0ahUKEwiLuqDLmeHTAhWHzIMKHak-C7AQFgg1MAM&url=http%3A%2F%2Fwww.searo.who.int%2Fentity%2Fsrilanka%2Fareas%2Ffilaria%2Flymphatic-filariasis-brochure-sri-lanka.pdf&usg=AFQjCNFXoIpWCStl7XF9F6qvJHFST577MA. Accessed on April 10, 2018.
  12. Irvine MA, Kazura JW, Hollingsworth TD, Reimer LJ, , 2018. Understanding heterogeneities in mosquito-bite exposure and infection distributions for the elimination of lymphatic filariasis. Proc Biol Sci 285: 20172253.
  13. Michael E, Singh BK, , 2016. Heterogeneous dynamics, robustness/fragility trade-offs, and the eradication of the macroparasitic disease, lymphatic filariasis. BMC Med 14: 14.
  14. Rao RU, Samarasekera SD, Nagodavithana KC, Dassanayaka TDM, Punchihewa MW, Ranasinghe USB, Weil GJ, , 2017. Reassessment of areas with persistent lymphatic filariasis nine years after cessation of mass drug administration in Sri Lanka. PLoS Negl Trop Dis 11: e0006066.
  15. Rao RU, Samarasekera SD, Nagodavithana KC, Punchihewa MW, Dassanayaka TD, P K D G, Ford E, Ranasinghe US, Henderson RH, Weil GJ, , 2016. Programmatic use of molecular xenomonitoring at the level of evaluation units to assess persistence of lymphatic filariasis in Sri Lanka. PLoS Negl Trop Dis 10: e0004722.
  16. Weil GJ, Ramzy RM, , 2007. Diagnostic tools for filariasis elimination programs. Trends Parasitol 23: 7882.
  17. Weil GJ, Curtis KC, Fischer PU, Won KY, Lammie PJ, Joseph H, Melrose WD, Brattig NW, , 2011. A multicenter evaluation of a new antibody test kit for lymphatic filariasis employing recombinant Brugia malayi antigen Bm-14. Acta Trop 120 (Suppl 1): S19S22.
  18. Rao RU, Atkinson LJ, Ramzy RM, Helmy H, Farid HA, Bockarie MJ, Susapu M, Laney SJ, Williams SA, Weil GJ, , 2006. A real-time PCR-based assay for detection of Wuchereria bancrofti DNA in blood and mosquitoes. Am J Trop Med Hyg 74: 826832.
  19. Katholi CR, Toe L, Merriweather A, Unnasch TR, , 1995. Determining the prevalence of Onchocerca volvulus infection in vector populations by polymerase chain reaction screening of pools of black flies. J Infect Dis 172: 14141417.
  20. Katholi CR, Unnasch TR, , 2006. Important experimental parameters for determining infection rates in arthropod vectors using pool screening approaches. Am J Trop Med Hyg 74: 779785.
  21. Yahathugoda TC, 2015. A comparison of two tests for filarial antigenemia in areas in Sri Lanka and Indonesia with low-level persistence of lymphatic filariasis following mass drug administration. Parasit Vectors 8: 369.
  22. WHO, 2017. Guideline—Alternative Mass Drug Administration Regimens to Eliminate Lymphatic Filariasis. Geneva, Switzerland: World Health Organization. WHO/HTM/NTD/PCT/2017.07, 1–50.
  23. Lau CL, Won KY, Becker L, Soares Magalhaes RJ, Fuimaono S, Melrose W, Lammie PJ, Graves PM, , 2014. Seroprevalence and spatial epidemiology of lymphatic filariasis in American Samoa after successful mass drug administration. PLoS Negl Trop Dis 8: e3297.
  24. Lau CL, Won KY, Lammie PJ, Graves PM, , 2016. Lymphatic filariasis elimination in American Samoa: evaluation of molecular xenomonitoring as a surveillance tool in the endgame. PLoS Negl Trop Dis 10: e0005108.
  25. Cano J, 2014. The global distribution and transmission limits of lymphatic filariasis: past and present. Parasit Vectors 7: 466.
  26. Lau CL, Sheridan S, Ryan S, Roineau M, Andreosso A, Fuimaono S, Tufa J, Graves PM, , 2017. Detecting and confirming residual hotspots of lymphatic filariasis transmission in American Samoa 8 years after stopping mass drug administration. PLoS Negl Trop Dis 11: e0005914.
  27. Harris JR, Wiegand RE, , 2017. Detecting infection hotspots: modeling the surveillance challenge for elimination of lymphatic filariasis. PLoS Negl Trop Dis 11: e0005610.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.18-0169
Loading
/content/journals/10.4269/ajtmh.18-0169
Loading

Data & Media loading...

Supplementary Data

Supplemental Tables

  • Received : 26 Feb 2018
  • Accepted : 22 Apr 2018

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error